Regeneron's antibody drug added to UK Recovery trial of COVI
Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...
Get authentic, real-time news that helps you fight COVID-19 better.
Install PlexusMD App for doctors. It's free.
The RECOVERY (Randomised Evaluation of Covid-19 therapy) Trial at the University of Oxford is all set to test its first specifically designed Covid-19 therapy — REGN-COV2 — which is a cocktail of antiviral antibodies, according to a statement issued on 14 September, by the university.

Phase 3 open-label trial in patients hospitalised with Covid-19 will compare the effects of adding REGN-COV2 to the usual standard-of-care versus standard-of-care on its own.

RECOVERY trial started with six arms — Lopinavir-Ritonavir, low-dose Dexamethasone (this arm is currently only recruiting children), Hydroxychloroquine (now stopped), Azithromycin, Tocilizumab and convalescent plasma.

In June and September, trial results showed that widely used steroids such as dexamethasone and hydrocortisone were able to reduce death rates among severely-ill COVID-19 patients

Also in June, RECOVERY trial results showed that the anti-malarial drug hydroxychloroquine was of no benefit in treating COVID-19 patients.

Regeneron's REGN-COV2 cocktail, which the company is already testing in late-stage clinical trials in people, combines one Regeneron-made antibody and a second antibody isolated from people who have recovered after being infected with COVID-19.

The combination is designed to bind to the spike protein used by the new coronavirus to gain access to human cells, limiting the virus's ability to escape.

Dr. T●●●●z H●●●●●●i and 4 others like this